schliessen

Filtern

 

Bibliotheken

Human monoclonal antibodies as candidate therapeutics against emerging viruses

The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antib... Full description

Journal Title: Frontiers of Medicine 2017, Vol.11(4), pp.462-470
Main Author: Jin, Yujia
Other Authors: Lei, Cheng , Hu, Dan , Dimitrov, Dimiter , Ying, Tianlei
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 2095-0217 ; E-ISSN: 2095-0225 ; DOI: 10.1007/s11684-017-0596-6
Link: http://dx.doi.org/10.1007/s11684-017-0596-6
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s11684-017-0596-6
title: Human monoclonal antibodies as candidate therapeutics against emerging viruses
format: Article
creator:
  • Jin, Yujia
  • Lei, Cheng
  • Hu, Dan
  • Dimitrov, Dimiter
  • Ying, Tianlei
subjects:
  • human monoclonal antibodies
  • emerging infectious diseases
  • SARS-CoV
  • MERS-CoV
  • Ebola virus
ispartof: Frontiers of Medicine, 2017, Vol.11(4), pp.462-470
description: The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
language: eng
source:
identifier: ISSN: 2095-0217 ; E-ISSN: 2095-0225 ; DOI: 10.1007/s11684-017-0596-6
fulltext: fulltext
issn:
  • 2095-0225
  • 20950225
  • 2095-0217
  • 20950217
url: Link


@attributes
ID355401208
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s11684-017-0596-6
sourceidspringer_jour
recordidTN_springer_jour10.1007/s11684-017-0596-6
sourcesystemPC
pqid1966294224
galeid518464642
display
typearticle
titleHuman monoclonal antibodies as candidate therapeutics against emerging viruses
creatorJin, Yujia ; Lei, Cheng ; Hu, Dan ; Dimitrov, Dimiter ; Ying, Tianlei
ispartofFrontiers of Medicine, 2017, Vol.11(4), pp.462-470
identifier
subjecthuman monoclonal antibodies ; emerging infectious diseases ; SARS-CoV ; MERS-CoV ; Ebola virus
descriptionThe emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1007/s11684-017-0596-6$$EView_full_text_in_Springer_(Subscribers_only)
search
creatorcontrib
0Jin, Yujia, S.
1Lei, Cheng, S.
2Hu, Dan, S.
3Dimitrov, Dimiter, S.
4Ying, Tianlei, S.
titleHuman monoclonal antibodies as candidate therapeutics against emerging viruses
descriptionThe emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
subject
0human monoclonal antibodies
1emerging infectious diseases
2SARS-CoV
3MERS-CoV
4Ebola virus
general
010.1007/s11684-017-0596-6
1English
2Springer Science & Business Media B.V.
3SpringerLink
sourceidspringer_jour
recordidspringer_jour10.1007/s11684-017-0596-6
issn
02095-0225
120950225
22095-0217
320950217
rsrctypearticle
creationdate2017
addtitle
0Frontiers of Medicine
1Front. Med.
searchscopespringer_journals_complete
scopespringer_journals_complete
lsr30VSR-Enriched:[galeid, pages, pqid]
sort
titleHuman monoclonal antibodies as candidate therapeutics against emerging viruses
authorJin, Yujia ; Lei, Cheng ; Hu, Dan ; Dimitrov, Dimiter ; Ying, Tianlei
creationdate20171200
facets
frbrgroupid6232536351472589260
frbrtype5
newrecords20171220
languageeng
creationdate2017
topic
0Human Monoclonal Antibodies
1Emerging Infectious Diseases
2Sars-Cov
3Mers-Cov
4Ebola Virus
collectionSpringerLink
prefilterarticles
rsrctypearticles
creatorcontrib
0Jin, Yujia
1Lei, Cheng
2Hu, Dan
3Dimitrov, Dimiter
4Ying, Tianlei
jtitleFrontiers Of Medicine
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Jin
1Lei
2Hu
3Dimitrov
4Ying
aufirst
0Yujia
1Cheng
2Dan
3Dimiter
4S.
5Tianlei
au
0Jin, Yujia
1Lei, Cheng
2Hu, Dan
3Dimitrov, Dimiter
4Ying, Tianlei
atitleHuman monoclonal antibodies as candidate therapeutics against emerging viruses
jtitleFrontiers of Medicine
stitleFront. Med.
risdate201712
volume11
issue4
spage462
epage470
issn2095-0217
eissn2095-0225
genrearticle
ristypeJOUR
abstractThe emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
copBeijing
pubHigher Education Press
doi10.1007/s11684-017-0596-6
pages462-470
date2017-12